Center Urged By Bharat Biotech to Include Incovacc in Cowin Portal


eMediNexus    14 December 2022

Bharat Biotech, a Covid vaccine manufacturer, has asked the union government to include their intranasal COVID vaccination, iNCOVACC, in the CoWIN portal. They requested to include it in the CoWin portal to enable the recipients to get vaccination certificates. The sources from the company stated that the manufacturers are holding discussions with "potential partners" to manufacture and distribute the intranasal vaccine globally.


The CoWin portal currently lists Bharat Biotech′s Covaxin, Serum Institute′s Covishield and Covovax, Russian Sputnik V, and Biological E Ltd.′s Corbevax. On September 6, the vaccine makers announced that iNCOVACC (BBV154) has received approval from the Drugs Controller General of India for restricted use in emergencies for ages 18 and above.


iNCOVACC (BBV154) was developed in partnership with Washington University in St. Louis, which designed, developed, and evaluated the recombinant adenoviral vector construct in pre-clinical studies for efficacy. 


(Source: https://www.thehindu.com/sci-tech/health/bharat-biotech-urges-centre-to-include-its-intranasal-covid-vaccine-in-cowin-portal/article66250858.ece )

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.